A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation

Current Neuropharmacology

Volumn 8, Issue 3, 2010, Pages 287-304

  Fornaro, Michele ^a   Prestia, Davide ^a   Colicchio, Salvatore ^b   Perugi, Giulio ^c,d  

^a UNIVERSITY OF GENOA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

Author keywords

Agomelatine; Alzheimer; Bipolar disorder; Cognition; Depression; Melatonin; Mood

Indexed keywords

2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; AGOMELATINE; ANTIDEPRESSANT AGENT; BUSPIRONE; CLOMIPRAMINE; CLORAZEPATE; DESIPRAMINE; DIAZEPAM; DOPAMINE; FLUMAZENIL; FLUOXETINE; FLUVOXAMINE; IBOTENIC ACID; IMIPRAMINE; IPSAPIRONE; LITHIUM; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; METHOHEXITAL; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROMIDE; VENLAFAXINE; VOFOPITANT;

AGING; AGONIST; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CIRCADIAN RHYTHM; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; COGNITION; COMPARATIVE STUDY; COMPREHENSION; DELIRIUM; DEPRESSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; EXTRACTION; GASTROINTESTINAL TOXICITY; GENE ORDER; GENERALIZED ANXIETY DISORDER; HORMONE SYNTHESIS; HUMAN; LIGHT; MAJOR DEPRESSION; MOOD DISORDER; MOTOR DYSFUNCTION; NARCOLEPSY; NAUSEA; NERVE CELL PLASTICITY; NONHUMAN; PANIC; PSYCINFO; RECEPTOR AFFINITY; REVIEW; SAFETY; SCREENING; SEASONAL AFFECTIVE DISORDER; SEXUAL DYSFUNCTION; SIDE EFFECT; SYNTHESIS; SYSTEMATIC REVIEW; TAXONOMY; TRANQUILIZING ACTIVITY; WEIGHT GAIN;

EID: 78549269430     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015910792246227     Document Type: Review

References (153)

1. Gaspar-Barba, E., Calati, R., Cruz-Fuentes, C.S., Ontiveros-Uribe, M.P., Natale, V., De Ronchi, D., Serretti, A. Depressive symptomatology is influenced by chronotypes. J. Affect Disord., 2009, 119(1-3), 100-6.
2. Mathers, C.D., Vos, E.T., Stevenson, C.E., Begg, S.J. The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk factors. Med. J. Aust., 2000, 172 (12), 592-6.
3. Racagni, G., Popoli, M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialog. Clin. Neurosci., 2008, 10(4), 385-400.
4. Papakostas, G.I., Fava, M. Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialog. Clin. Neurosci., 2008, 10(4), 439-51.
5. Rush, A.J., STAR*D. what have we learned? Am. J. Psychiatry, 2007, 164(2), 201-4.
6. Trivedi, M.H., Daly, E.J. Treatment strategies to improve and sustain remission in major depressive disorder. Dialog. Clin. Neurosci., 2008, 10(4), 377-84.
7. Krueger, F. R., Bezdjian. S. Enhancing research and treatment of mental disorders with dimensional concepts: toward DSM-V and ICD-11. World Psychiatry, 2009, 8(1), 3-6.
8. Tint, A., Haddad, P.M., Anderson, M. The effect of rate of anti-depressant tapering on the incidence of discontinuation symptoms: a randomised study. J. Psychopharmacol., 2008, 22(3), 330-2.
9. Sonawalla, S. B., Fava, M. Severe depression: is there a best approach? CNS Drugs, 2001, 15(10), 765-76.
10. Vestergaard, P., Gram, L.F., Kragh-Sorensen, P., Bech, P., Reisby, N., Bolwig, T.G. Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group. Psychopharmacol. Ser., 1993, 10, 190-8.
11. Hindmarch, I., Kimber, S., Cockle, S.M. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int. Clin. Psychopharmacol., 2000, 15(6), 305-18.
12. Judge, R., Parry, M.G., Quail, D., Jacobson, J, G. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int. Clin. Psychopharmacol., 2002, 17(5), 217-25.
13. Michelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., Tepner. R.G. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br. J. Psychiatry, 2000, 176, 363-8.
14. Rosenbaum, J.F., M. Fava, S.L. Hoog, R.C., Ascroft Krebs W.B. Selective seroto nin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol. Psychiatry, 1998, 44(2), 77-87.
15. Montgomery, S.A., Kennedy, S.H., Burrows, G.D., Lejoyeux, I. M. Hindmarch. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol., 2004, 19(5), 271-80.
16. Meek, C. SSRI ads questioned. CMAJ, 2006, 174(6), 754.
17. Belmaker, R.H. The future of depression psychopharmacology. CNS Spectr., 2008, 13(8), 682-7.
18. Olie, J., Kasper, P.S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int. J. Neuropsychopharmacol., 2000, 10(5), 661-73.
19. Srinivasan, V., Pandi-Perumal, S.R., Trakht, I., Spence, D.W., Hardeland, R., Poeggeler, B., Cardinali D.P. Pathophysiology of depression: Role of sleep and the melatonergic system. Psychiatry Res., 2009, 165(3), 201-14.
20. Van Reeth, O., Olivares, E., Zhang, Y., Zee, P.C., Mocaer, E., Defrance, R., Turek, F.W. Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters. Brain Res., 1997, 762(1-2), 185-94.
21. Svestka, J. Sleep deprivation therapy. Neuro Endocrinol. Lett., 2008, 29(Suppl1), 65-92.
22. Mendlewicz, J. Sleep disturbances: Core symptoms of major depressive disorder rather than associated or comorbid disorders. World J. Biol. Psychiatry, 2009, 1-7.
23. Grassi-Zucconi, G., Semprevivo, M., Mocaer, E., Kristensson K., Bentivoglio, M. Melatonin and its new agonist S-20098 restore synchronized sleep fragmented by experimental trypanosome infection in the rat. Brain Res., Bull, 1996, 39(2), 63-8.
24. Weibel, L., Turek, F.W., Mocaer, E., Van Reeth, O. A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle. Brain Res., 2000, 880(1-2), 207-11.
25. Kasper, S., Hamon, M. Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action. World J. Biol. Psychiatry, 2009, 1-11.
26. Masand, P.S., Gupta, S. Selective serotonin-reuptake inhibitors: an update. Harv. Rev. Psychiatry, 1999, 7(2), 69-84.
27. Anderson, I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect Disord., 2000, 58(1), 19-36.
28. European.Medicines.Agency, Refusal CHMP assessment and report thymanax, in Evaluation of medicines for human use.
29. Zupancic, M. Guilleminault, C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs, 2006, 20(12), pp. 981-92.
30. Dolder, C.R., Nelson, M., Snider, M. Agomelatine treatment of major depressive disorder. Ann. Pharmacother., 2008, 42 (12), 1822-31.
31. Masson-Pevet, M., Recio, J., Guerrero, H.Y., Mocaer, E, Delagrange, P., Guardiola-Lemaitre, B., Pevet, P. Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in the pars tuberalis of the rat. J. Pineal. Res., 1998, 25(3), 172-6.
32. Millan, M.J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi, A., Pasteau, V., Rivet J.M., Cussac, D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther., 2003, 306(3), 954-64.
33. Stam, N.J., Vanderheyden, P., van Alebeek, C., Klomp, J., de Boer, T., van Delft, A.M., Olijve, W. Genomic organisation and functional expression of the gene encoding the human serotonin 5-HT2C receptor. Eur. J. Pharmacol., 1994, 269(3), 339-48.
34. Shelton, R. C., Papakostas, G.I. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr. Scand., 2008, 117(4), 253-9.
35. Jenck, F., Bos, M., Wichmann, J., Stadler, H., Martin, J.R Moreau, J.L. The role of 5-HT2C receptors in affective disorders. Expert Opin. Investig. Drugs, 1998, 7(10), 1587-99.
36. Millan, M.J. Dual-and triple-acting agents for treating core and comorbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics, 2009, 6(1), 53-77.
37. Alex, K.D., Yavanian, G.J., McFarlane, H.G., Pluto, C.P., Pehek, E.A. Modulation of dopamine release by striatal 5-HT2C receptors. Synapse, 2005, 55(4), 242-51.
38. Papp, M., Gruca, P., Boyer, P. A., Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology, 2003, 28(4), 694-703.
39. Leysen, D.C. Selective 5-HT2C agonists as potential anti-depressants. IDrugs, 1999, 2(2), 109-20.
40. Lam, R.W. Sleep disturbances and depression: a challenge for antidepressants. Int. Clin. Psychopharmacol., 2006, 21(Suppl 1), S25-9.
41. Hanoun, N., Mocaer, E., Boyer, P.A., Hamon, M., Lanfumey, L. Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology, 2004, 47(4), 515-26.
42. Pandi-Perumal, S.R., Srinivasan, V., Cardinali, D.P., Monti M.J. Could agomelatine be the ideal antidepressant? Expert Rev. Neurother., 2006, 6(11), 1595-608.
43. Ruan, G.X., Allen, G.C., Yamazaki, S., McMahon, D.G. An autonomous circadian clock in the inner mouse retina regulated by dopamine and GABA. PLoS Biol., 2008, 6(10), p. e249.
44. Lorenc-Duda, A., Berezinska, M., Urbanska, A., Golembiowska, K., Zawilska, J.B. Dopamine in the Turkey Retina-An Impact of Environmental Light, Circadian Clock, and Melatonin. J. Mol. Neurosci., 2008.
45. Rudolf, G., Vivien-Roels, B., Pevet, P., Kempf, E. Wioland, N. Dopamine and melatonin interactions in the intact chicken eye. Electrooculographic and biochemical study. Brain Res., 1992, 584(1-2), 64-70.
46. Rudolf, G., Wioland, N., Kempf, E., Bonaventure, N. EOG and ERG modifications induced in the chicken eye after blockade of catecholamine and 5-hydroxytryptamine biosynthesis. Doc. Ophthalmol., 1990, 76(1), 47-53.
47. Fornaro, P., Castrogiovanni, P., Perossini, M., Placidi, G.F., Cavallacci, G. Electroretinography (ERG) as a tool of investigation in human psychopharmacology. Electroretinographic changes induced by a combination of carbi-dopa and levo-dopa. Acta Neurol (Napoli), 1980, 2(4), 293-9.
48. Perossini, M., Fornaro, P. Electroretinographic effects induced in humans by psychopharmacologic agents. Doc. Ophthalmol., 1990, 75(1), 1-6.
49. Lam, R.W., Beattie, C.W., Buchanan, A.J., Mador, A. Electroretinography in seasonal affective disorder. Psychiatry Res, 1992, 43(1), 55-63.
50. Shirayama, Y., Chaki, S. Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents. Curr. Neuropharmacol., 2006, 4(4), 277-91.
51. Racagni, G., Riva, M.A., Popoli, M. The interaction between the internal clock and antidepressant efficacy. Int. Clin. Psychopharmacol., 2007, 22(Suppl 2), S9-S14.
52. Loiseau, F., Millan, M.J. Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists. Eur. Neuropsychopharmacol, 2009, 19(1), 23-33.
53. Millan, M.J., Gobert, A., Panayi, F., Rivet, J.M., Dekeyne, A., Brocco, M., Ortuno, J.C., Di Cara, B. The melanin-concentrating hormone1 receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats. Int. J. Neuropsychopharmacol., 2008, 11(8), pp. 1105-22.
54. Chu, Y.S., Shieh, K.R., Yuan, Z.F., Pan, J.T. Stimulatory and entraining effect of melatonin on tuberoinfundibular dopaminergic neuron activity and inhibition on prolactin secretion. J. Pineal. Res., 2000, 28(4), pp. 219-26.
55. San, L. Arranz, B. Agomelatine: a novel mechanism of anti-depressant action involving the melatonergic and the serotonergic system. Eur. Psychiatry, 2008, 23(6), 396-402.
56. Srinivasan, V., Spence, D.W., Pandi-Perumal, S.R., Trakht, I., Cardinali, D.P. Jet lag: therapeutic use of melatonin and possible application of melatonin analogs. Travel Med. Infect. Dis., 2008, 6(1-2), 17-28.
57. Srinivasan, V., Pandi-Perumal, S.R., Trahkt, I., Spence, D.W., Poeggeler, B., Hardeland, R., Cardinali, D.P. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int. J. Neurosci., 2009, 119(6), 821-46.
58. Gross, P.K., Nourse, R., Wasser, T.E. Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study. J. Clin. Sleep Med., 2009, 5(1), 28-33.
59. Rajaratnam, S.M., Polymeropoulos, M.H., Fisher, D.M., Roth, T., Scott, C., Birznieks, G., Klerman E.B., Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet, 2009, 373(9662), 482-91.
60. Ying, S.W., Rusak, B., Mocaer, E. Chronic exposure to melatonin receptor agonists does not alter their effects on suprachiasmatic nucleus neurons. Eur. J. Pharmacol., 1998, 342(1), 29-37.
61. Redman, J.R., Francis, A.J. Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal. J. Biol. Rhythms, 1998, 13(1), 39-51.
62. Tuma, J., Strubbe, J.H., Mocaer, E., Koolhaas, J.M. Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN. Eur. Neuropsycho-pharmacol., 2005, 15(5), 545-55.
63. Redman, J.R., Guardiola-Lemaitre, B., Brown, M., Delagrange, P. Armstrong, S.M. Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology (Berl), 1995, 118(4), 385-90.
64. Martinet, L., Guardiola-Lemaitre, B., Mocaer, E. Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol. Biochem. Behav., 1996, 54(4), 713-8.
65. Karasek, M.; Melatonin, human aging, and age-related diseases. Exp. Gerontol., 2004, 39(11-12), 1723-9.
66. Tarquini, B., Perfetto, F., Tarquini, R. [Melatonin: a popular hormone]. Minerva Med., 1998, 89(5), 139-51.
67. Leproult, R., Van Onderbergen, A., L'hermite-Baleriaux, M., Van Cauter, E. Copinschi, G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin. Endocrinol. (Oxf), 2005, 63(3), 298-304.
68. Van Reeth, O., Weibel, L., Olivares, E., Maccari, S., Mocaer, E., Turek, F.W. Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 280(5), R1582-91.
69. Mongrain, V., Carrier, J., Dumont, M. Circadian and homeostatic sleep regulation in morningness-eveningness. J. Sleep Res., 2006, 15(2), 162-6.
70. Arushanian, E.B., Baida, O.A., Mastiagin, S.S. [Effect of melatonin on memory, individual time perception, and anxiety in young people of different chronotype groups]. Eksp. Klin. Farmako., 2006, 69(1), 21-3.
71. Danilenko, K.V., Putilov, A.A. Melatonin treatment of winter depression following total sleep deprivation: waking EEG and mood correlates. Neuropsychopharmacology, 2005, 30(7), 1345-52.
72. Roberts, J.E., Wiechmann, A.F., Hu, D.N. Melatonin receptors in human uveal melanocytes and melanoma cells. J. Pineal Res., 2000, 28(3), 165-71.
73. Evans, J.A., Elliott, J.A., Gorman, M.R. Dim nighttime illumination accelerates adjustment to timezone travel in an animal model. Curr. Biol., 2009, 19(4), R156-7.
74. Pandi-Perumal, S.R., Srinivasan, V., Spence D.W., Cardinali, D.P. Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs, 2007, 21(12), 995-1018.
75. Armstrong, S.M., McNulty, O.M., Guardiola-Lemaitre, B., Redman, J.R. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol. Biochem. Behav., (1993), 46(1), 45-9.
76. Prasko, J. Bright light therapy. Neuro Endocrinol. Lett., 2008, 29(Suppl1), 33-64.
77. Pjrek, E., Winkler, D., Konstantinidis, A., Willeit, M., Praschak-Rieder, N., Kasper, S. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl), 2007, 190(4), 575-9.
78. Kalsbeek, A., La Fleur, S., Van Heijningen, C., Buijs, R.M. Suprachiasmatic GABAergic inputs to the paraventricular nucleus control plasma glucose concentrations in the rat via sympathetic innervation of the liver. J. Neurosci., 2004, 24(35), 7604-13.
79. Paula-Lima, A.C., Louzada, P.R., De Mello, F.G., Ferreira S.T. Neuroprotection against Abeta and glutamate toxicity by melatonin: are GABA receptors involved? Neurotox. Res., 2003, 5(5), 323-7.
80. Wan, Q., Man, H.Y., Liu, F., Braunton, J., Niznik, H.B., Pang, S.F., Brown, G.M., Wang, Y. T. Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors. Nat. Neurosci., 1999, 2(5), 401-3.
81. Eser, D., Baghai, T.C., Moller, H.J. Evidence of agomelatine's antidepressant efficacy: the key points. Int. Clin. Psychopharmacol., 2007, 22(Suppl 2), S15-9.
82. Wagner, J., Wagner, M.L., Hening, W.A. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann. Pharmacother., 1998, 32(6), 680-91.
83. Millan, M. J., Brocco, M., Gobert, A., Dekeyne, A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl), 2005, 177(4), 448-58.
84. Wiley, J.L., Dance, M.E., Balster, R.L. Preclinical evaluation of the reinforcing and discriminative stimulus effects of agomelatine (S-20098), a melatonin agonist. Psychopharmacology (Berl), 1998, 140(4), 503-9.
85. Papp, M., Litwa, E., Gruca, P., Mocaer, E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav. Pharmacol., 2006, 17(1), 9-18.
86. Loiseau, F., Le Bihan, C., Hamon, M., Thiebot, M.H. Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam. Eur. Neuropsychopharmacol., 2006, 16(6), 417-28.
87. Stein, D.J., Ahokas, A.A., de Bodinat, C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol., 2008, 28(5), 561-6.
88. Larson, J., Jessen, R.E., Uz, T., Arslan, A.D., Kurtuncu, M., Imbesi, M., Manev, H. Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice. Neurosci. Lett., 2006, 393(1), 23-6.
89. Conboy, L., Tanrikut, C., Zoladz, P.R., Campbell, A.M., Park, C.R., Gabriel, C., Mocaer, E., Sandi, C. Diamond, D.M. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int. J. Neuropsychopharmacol., 2009, 12(3), 329-41.
90. Pappolla, M.A., Sos, M., Omar, R.A., Bick, R.J., Hickson-Bick, D.L., Reiter, R.J., Efthimiopoulos, S., Robakis, N.K. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J. Neurosci., 1997, 17(5), 1683-90.
91. Ortiz, G.G., Benitez-King, G.A., Rosales-Corral, S.A., Pacheco-Moises, F.P., Velazquez-Brizuela, I.E. Cellular and biochemical actions of melatonin which protect against free radicals: Role in neurodegenerative disorders. Curr. Neuropharmacol., 2008, 6(3), 203-214.
92. Wang, X.C., Zhang, J., Yu, X., Han, L., Zhou, Z.T., Zhang, Y., Wang, J.Z. Prevention of isoproterenol-induced tau hyper-phosphorylation by melatonin in the rat. Sheng Li Xue Bao, 2005, 57(1), 7-12.
93. Zisapel, N.; Melatonin-dopamine interactions: from basic neuro-chemistry to a clinical setting. Cell Mol. Neurobiol., 2001, 21(6), 605-16.
94. Tenn, C.C., Niles, L.P. The antidopaminergic action of S-20098 is mediated by benzodiazepine/GABA(A) receptors in the striatum. Brain Res., 1997, 756(1-2), 293-6.
95. Pitrosky, B., Kirsch, R., Malan, A., Mocaer, E., Pevet, P. Organization of rat circadian rhythms during daily infusion of melatonin or S20098, a melatonin agonist. Am. J. Physiol., 1999, 277(3 Pt 2), R812-28.
96. Fornaro, P., Calabria, G., Corallo, G., Picotti, G.B. Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis. Doc. Ophthalmol., 2002, 105(1), 41-9.
97. Extrapyramidal effects of SSRI antidepressants. Prescrire Int., 2001, 10(54), 118-9.
98. Castren, E. Is mood chemistry? Nat. Rev. Neurosci., 2005, 6(3), 241-6.
99. Duman, R.S., Malberg, J., Thome, J. Neural plasticity to stress and antidepressant treatment. Biol. Psychiatry, 1999, 46(9), 1181-91.
100. Manji, H.K. Duman, R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol. Bull., 2001, 35(2), 5-49.
101. Manji, H.K., Moore, G.J., Rajkowska, G., Chen, G. Neuroplasticity and cellular resilience in mood disorders. Mol. Psychiatry, 2000, 5(6), 578-93.
102. Gressens, P., Schwendimann, L., Husson, I., Sarkozy, G., Mocaer, E., Vamecq, J., Spedding, M. Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity. Eur. J. Pharmacol., 2008, 588(1), 58-63.
103. Bourin, M., Mocaer, E., Porsolt, R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J. Psychiatry Neurosci., 2004, 29(2), 126-33.
104. Van Reeth, O., Olivares, E., Turek, F.W., Granjon, L., Mocaer, E. Resynchronisation of a diurnal rodent circadian clock accelerated by a melatonin agonist. Neuroreport, 1998, 9(8), 1901-5.
105. Tuma, J., Strubbe, J.H., Mocaer, E., Koolhaas, J.M. S20098 affects the free-running rhythms of body temperature and activity and decreases light-induced phase delays of circadian rhythms of the rat. Chronobiol. Int., 2001, 18(5), 781-99.
106. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders DSM-IV. Washington, DC: APA; 1994.
107. Kegel, M., Dam, H., Ali, P, Bjerregaard, F. The prevalence of seasonal affective disorder (SAD) in Greenland is related to latitude. Nord. J. Psychiatry, 2009, 1-5.
108. Rosenthal, N.E., Sack, D.A., Gillin, J.C., Lewy, A.J., Goodwin, F.K., Davenport, Y., Mueller, P.S., Newsome D.A., Wehr, T. A. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch. Gen. Psychiatry, 1984, 41(1), 72-80.
109. Johansson, C., Willeit, M., Smedh, C., Ekholm, J., Paunio, T., Kieseppa, T., Lichtermann, D., Praschak-Rieder, N., Neumeister, A., Nilsson, L.G., Kasper, S., Peltonen, L., Adolfsson, R., Schalling, M., Partonen, T. Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology, 2003, 28(4), 734-9.
110. Rudorfer, M.V., Skwerer, R.G., Rosenthal, N.E. Biogenic amines in seasonal affective disorder: effects of light therapy. Psychiatry Res., 1993, 46(1), 19-28.
111. Bhattacharjee, Y. Psychiatric research. Is internal timing key to mental health? Science, 2007, 317(5844), 1488-90.
112. Sohn, C.H., Lam, R.W. Update on the biology of seasonal affective disorder. CNS Spectr., 2005, 10(8), 635-46; quiz 1-14.
113. Ehlers, C.L., Frank, E., Kupfer, D.J. Social zeitgebers and biological rhythms. A unified approach to understanding the etiology of depression. Arch. Gen. Psychiatry, 1988, 45(10), 948-52.
114. Murray, C.J., Lopez, A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet, 1997, 349(9063), 1436-42.
115. Ghaemi, S.N., Sachs, G.S., Chiou, A.M., Pandurangi, A.K., Goodwin, K. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? J. Affect Disord., 1999, 52(1-3), 135-44.
116. Judd, L.L., Akiskal, H.S., Schettler, P.J., Endicott, J., Maser, J., Solomon, D.A., Leon, A.C., Rice, J.A., Keller, M.B. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry, 2002, 59(6), 530-7.
117. Post, R.M., Denicoff, K.D., Leverich, G.S., Altshuler L.L, Frye, M.A., Suppes, T.M., Rush, A.J., Keck Jr. P.E., McElroy, S.L., Luckenbaugh, D.A., Pollio, C., Kupka, R., Nolen, W.A. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J. Clin. Psychiatry, 2003, 64(6), 680-90, quiz 738-9.
118. Judd, L.L., Akiskal, H.S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J.D., Solomon, D.A., Leon, A.C., Keller, M.B. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry, 2003, 60(3), 261-9.
119. Lewy, A.J., Nurnberger, Jr. J.I., Wehr, T.A., Pack, D., Becker, L.E., Powell, R.L., Newsome, D.A. Supersensitivity to light: possible trait marker for manic-depressive illness. Am. J. Psychiatry, 1985, 142(6), 725-7.
120. Whalley, L.J., Perini, T. Shering, A., Bennie, J. Melatonin response to bright light in recovered, drug-free, bipolar patients. Psychiatry Res., 1991, 38(1), 13-9.
121. Gao, K.J., Calabrese, R. Newer treatment studies for bipolar depression. Bipolar Disord., 2005, 7(Suppl 5), 13-23.
122. Wetterberg, L. Clinical importance of melatonin. Prog. Brain Res., 1979, 52, 539-47.
123. Rubin, R.T., Heist, E.K., McGeoy, S.S., Hanada K., Lesser, M. Neuroendocrine aspects of primary endogenous depression. XI. Serum melatonin measures in patients and matched control subjects. Arch. Gen. Psychiatry, 1992, 49(7), 558-67.
124. Crasson, M., Kjiri, S., Colin, A., Kjiri, K., L 'Hermite-Baleriaux, M., Ansseau, M., Legros, J.J. Serum melatonin and urinary 6-sulfatoxymelatonin in major depression. Psychoneuroendocri-nology, 2004, 29(1), 1-12.
125. Kripke, D.F., Jean-Louis, G. Elliott, J.A. Klauber, M.R., Rex, K.M., Tuunainen, A., Langer, R.D. Ethnicity, sleep, mood, and illumination in postmenopausal women. BMC Psychiatry, 2004, 4, 8.
126. Robertson, E., Jones, I., Haque, S., Holder, R., Craddock, N. Risk of puerperal and non-puerperal recurrence of illness following bipolar affective puerperal (post-partum) psychosis. Br. J. Psychiatry, 2005, 186, 258-9.
127. Bunney, W.E., Jr., Murphy, D.L. Goodwin, F.K., Borge, G.F. The switch process from depression to mania: relationship to drugs which alter brain amines. Lancet, 1970, 1(7655), 1022-7.
128. Souetre, E., Salvati, E., Belugou, J.L., Pringuey, D., Candito, M., Krebs, B., Ardisson, J.L., Darcourt, G. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res., 1989, 28(3), 263-78.
129. Fuchs, E., Simon, M., Schmelting, B. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int. Clin. Psychopharmacol., 2006, 21(Suppl 1), pp. S17-20.
130. Detanico, B.C., Piato, A.L., Freitas, J.J., Lhullier, F.L., Hidalgo, M.P., Caumo, W., Elisabetsky, E. Antidepressant-like effects of melatonin in the mouse chronic mild stress model. Eur. J. Pharmacol., 2009, 607(1-3), 121-5.
131. Bertaina-Anglade, V., la Rochelle, C.D., Boyer, P.A. Mocaer, E. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav. Pharmacol., 2006, 17(8), 703-13.
132. Barden, N., Shink, E., Labbe, M., Vacher, R., Rochford, J., Mocaer, E. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2005, 29(6), 908-16.
133. Benazzi, F. 2005, Severity gradation of the Montgomery Asberg Depression Rating Scale (MADRAS) in outpatients. J. Psychiatry Neurosci., 1999, pp. 24(1), 51-2.
134. Fleck, M.P., Poirier-Littre, M.F., Guelfi, J.D., Bourdel, M.C., Loo, H. Factorial structure of the 17-item Hamilton Depression Rating Scale. Acta Psychiatr. Scand., 1995, 92(3), 168-72.
135. Montgomery, S., Kasper, A.S. Severe depression and anti-depressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int. Clin. Psychopharmacol., 2007, 22(5), 283-91.
136. Sonntag, A., Rothe, B., Guldner, J., Yassouridis, A., Holsboer, F. Steiger, A. Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression, 1996, 4(1), 1-13.
137. Trivedi, M.H., Rush, A.J., Armitage, R., Gullion, C.M., Grannemann, B.D., Orsulak, P.J., Roffwarg, H.P. Effects of fluoxetine on the polysomnogram in outpatients with major depression. Neuropsychopharmacology, 1999, 20(5), 47-59.
138. Quera, S. M. A., Vanier, B., Laredo, J., Hartley, S., Chapotot, F., Moulin, C., Lofaso, F., Guilleminault, C. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int. J. Neuropsychopharmacol., 2007, 10(5), 691-6.
139. Lemoine, P., Guilleminault, C., Alvarez, E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J. Clin. Psychiatry, 2007, 68(11), 1723-32.
140. Kennedy, S.H., Rizvi, S., Fulton, K., Rasmussen, J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J. Clin. Psychopharmacol., 2008, 28(3), 329-33.
141. Ghosh, A.J., Hellewell, S. A review of the efficacy and tolerability of agomelatine in the treatment of major depression. Expert Opin. Investig. Drugs, 2007, 16(12), 1999-2004.
142. Loo, H., Dalery, J., Macher APayen, J.P. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin-agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders]. Encephale, 2003, 29(2), 165-71.
143. Rosen, R.C., Lane, R.M., Menza, M. Effects of SSRIs on sexual function: a critical review. J. Clin. Psychopharmacol., 1999, 19(1), 67-85.
144. Kennedy, S. H., Emsley, R Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsycho-pharmacol., (2006)16(2), 93-100.
145. Montejo, A., Prieto, N., Terleira, A., Matias, J., Alonso, S., Paniagua, G., Naval, S., Parra, D., Gabriel, C., Mocaer, E., Portoles, A. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J. Psychopharmacol., 2010, 24, 111-120.
146. Goodwin, G.M., Emsley, R., Rembry, S. Rouillon, F. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry, 2009, 70(8), 1128-37.
147. Zajecka, J., Schatzberg, A., Stahl, S., Shah, A., Caputo, A., Post, A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled Trial. J. Clin. Psychopharmacol., 2010, 30(2), 135-144.
148. McAllister-Williams, R.H., Baldwin, D.S., Haddad, P.M., Bazire, S. The use of antidepressants in clinical practice: focus on agomelatine. Hum. Psychopharmacol., 2010, 25(2), 95-102.
149. Stahl, S.M., Fava, M., Trivedi, M.H., Caputo, A., Shah, A., Post A. agomelatine in the treatment of major depressive Disorder: An 8-Week, multicenter, randomized, placebo-controlled trial. J. Clin. Psychiatry, (2010) March 23. Online ahead of print. (doi:10.4088/ JCP.09m05471blu).
150. Howland, R.H. Agomelatine: a novel atypical antidepressant. J. Psychosoc. Nurs. Ment. Health Serv., 2007, 45(12), 13-7.
151. den Boer, J.A., Bosker, F.J., Meesters, Y. Clinical efficacy of agomelatine in depression: the evidence. Int. Clin. Psychopharmacol., 2006, 21(Suppl 1), pp. S21-4.
152. Loo, H., Hale, A., D'Haenen, H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol., 2002, 17(5), 239-47.
153. Rouillon, F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int. Clin. Psychopharmacol., 2006, 21(Suppl 1), S31-5.